PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders
PharmaCyte Biotech, Inc. (OTCQB: PMCB) announced that all four proposals presented at its 2021 Annual Meeting of Stockholders passed. The meeting, held on June 16 and adjourned until June 30, resulted in:
- Election of seven directors for one-year terms.
- Approval to increase the number of authorized shares.
- Approval of the 2021 Equity Incentive Plan.
- Ratification of Armanino LLP as the independent accounting firm for the fiscal year ending April 30, 2022.
This progress supports the development of their cellular therapies for cancer and diabetes.
- All four proposals at the Annual Meeting passed, allowing for strategic direction and governance.
- The increase in authorized shares can facilitate future fundraising efforts.
- Approval of the 2021 Equity Incentive Plan may improve employee retention and motivation.
- Continued partnership with Armanino LLP supports transparency and compliance.
- None.
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that all 4 proposals presented to the Company’s stockholders for a vote at the 2021 Annual Meeting of Stockholders have passed.
PharmaCyte’s 2021 Annual Meeting of Stockholders was held on June 16, 2021, and then adjourned until voting concluded on June 30, 2021. The following proposals were approved at the Annual Meeting:
- Proposal One: To elect seven directors as nominated by the Board of Directors, each to serve a one-year term.
- Proposal Two: To approve a Certificate of Amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock of the Company.
- Proposal Three: To approve the Company’s 2021 Equity Incentive Plan.
- Proposal Four: To ratify the appointment of Armanino LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2022.
To learn more about PharmaCyte’s pancreatic cancer therapy and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch PharmaCyte’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and we believe results in little to no treatment related side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human liver cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is also considering the use of genetically modified stem cells to treat diabetes. The encapsulation of the cell lines will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a “bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance, and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward- looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005301/en/
FAQ
What proposals were approved at PharmaCyte Biotech's 2021 Annual Meeting?
When was PharmaCyte Biotech's 2021 Annual Meeting held?
What is the significance of increasing authorized shares for PMCB?
Who was ratified as PharmaCyte's independent accounting firm for 2021?
What does PharmaCyte's Equity Incentive Plan entail?
